Status:
COMPLETED
Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide
Lead Sponsor:
Hvidovre University Hospital
Collaborating Sponsors:
Zealand Pharma
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
MALE
18-80 years
Brief Summary
The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes....
Eligibility Criteria
Inclusion
- Type 2 diabetes
- BMI \> 27 kg/m2
- Planed start of treatment with liraglutide
- Age \> 18 years
Exclusion
- Infection or active inflammatory disorder
- Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
- Smoking
- Alcohol consumption \> 14 beverages/week
- Former bariatric surgery
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT02201550
Start Date
February 1 2013
End Date
April 1 2014
Last Update
July 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hvidovre University Hospital
Hvidovre, Denmark, 2650